ASHBURN, Va., July 21 /PRNewswire/ -- Innocoll Inc. today announced that Anthony H. Wild, Ph.D. has been appointed to its board of directors.
Dr. Wild is a co-founder and General Partner of BOWS Pharmaceuticals AG, a Swiss drug-delivery technology company. He is a member of the Boards of Directors of several privately-owned specialty pharmaceutical and biotechnology companies. He also chairs the board of advisors of Ferrer, Freeman and Co., a healthcare private equity firm. He is on the board of advisors of Celtic Therapeutics, a pharmaceutical venture fund and is an advisor to Golden Pond Healthcare Inc., a special acquisitions corporation.
Dr. Wild was the Chairman of MedPointe Pharmaceuticals Inc., a privately-held specialty pharmaceutical company based in Somerset (NJ), until its acquisition by Meda AB of Sweden in 2007. He also served as CEO from 2001 until 2006.
Between 1995 and 2000, Dr Wild worked for the Warner-Lambert Company, of Morris Plains (NJ). Starting as President of Warner-Lambert's Parke-Davis (North America) unit, he was promoted to Executive Vice President and President of its global Pharmaceutical Sector in 1996. Before joining Warner-Lambert, Dr. Wild spent 22 years with the Schering-Plough Corporation in various roles culminating as President of its Japanese operations.
Dr. Wild graduated in 1968 from the University of York where he earned an honors degree in Chemistry. He also holds a Ph.D. degree in physical chemistry from the University of Cambridge (Churchill College).
"We are very fortunate to have Dr. Wild join our board, particularly at
this time in Innocoll's aggressive evolution to a world leader in
biodegradable surgical products. I have known Tony for a number of years
and have found him to be a skillful and successful executive in his prior
positions. Innocoll is gaining another professional member to its board to
guide the company through this period of ambitious growth," said Rolf
|SOURCE Innocoll Inc.|
Copyright©2008 PR Newswire.
All rights reserved